Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Emerg Drugs. 2011 Sep;16(3):493-505. doi: 10.1517/14728214.2011.581662. Epub 2011 Apr 30.

Emerging drugs to treat juvenile idiopathic arthritis.

Author information

  • 1IRCCS Istituto G Gaslini Pediatria II, Reumatologia, Genova, Italy.

Abstract

INTRODUCTION:

Juvenile idiopathic arthritis (JIA) differs markedly from adult rheumatoid arthritis (RA). It is not a single disease, but an exclusion diagnosis that gathers together all forms of arthritis that begin before the age of 16 years, persist for > 6 weeks and are of unknown origin. This heterogeneous group of disorders has been classified on clinical and laboratory features to try to identify homogeneous, mutually exclusives categories. While some of them appear to represent rather homogenous entities others still seem to include heterogeneous conditions.

AREAS COVERED:

The advent of new biological treatments has dramatically changed both the observed responses to treatment and the expectations of therapies. The implementation of an adequate legislation as well as the presence of international research networks of pediatric rheumatology have contributed to foster the conduct of controlled clinical trials and the development of validated outcome measures.

EXPERT OPINION:

Despite these progresses, there are still many problems to be solved to provide a better treatment for those patients who fail to adequately respond to current therapies. Some of the new drugs that are under investigation for RA could also be suitable in the future for improving the treatment of JIA.

PMID:
21529300
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk